Viva Star Bioscience
Viva Star Bio is advancing proprietary and differentiated assets (LPAR1 antagonist and NLRP3 inhibitors) for the treatment of respiratory disorders such as pulmonary fibrosis, asthma, etc.
January 12-15, 2026 | San Francisco Marriott Marquis, CA
Viva Star Bio is advancing proprietary and differentiated assets (LPAR1 antagonist and NLRP3 inhibitors) for the treatment of respiratory disorders such as pulmonary fibrosis, asthma, etc.